Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 554 participants.

Also called NCT04858308

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 554 participants (planned count) (from the registry)
Sponsor
Yooyoung Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT04858308
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04858308. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-29 (actual); primary completion 2021-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.
Acronym
Atorf-YOOrct
Condition
Dyslipidemias
Intervention (Drug)
YYC506
Intervention (Drug)
Control
Intervention (Drug)
YYC506 Placebo
Intervention (Drug)
Control Placebo
Lead sponsor
Yooyoung Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04858308
Content hash
09fa0ec813401058d962739ce919307f15c6daae66baa86ba8e8bc1440a4bdcf